Prescription Medicines
HyalbonePlus Inj.
- Product Category
- Osteoarthritis treatment
- Active Ingredients
- Sodium hyaluronate
- Appearance
- A colorless, transparent, viscous liquid contained in a glass tube (part of a prefilled syringe system) closed with a rubber stopper at the top and bottom.
- Reimbursement Code
- 648103691
01 / 02
1. Composition and Strength : In 1mL
- Active ingredient: Sodium hyaluronate (EP) ----- 10 mg
- Additives: Sodium chloride, sodium monohydrogen phosphate, sodium dihydrogen phosphate, water for injection
2. Effectiveness
Treatment of osteoarthritis of the knee joint and periarthritis of the shoulder
3. Dosage and dosage
Usually, adults administer one tube once a week into the knee joint space or shoulder joint (shoulder joint space, subacromial synovial vacuole, or biceps brachii tendon sheath) for 3 consecutive weeks. However, the number of administrations is appropriate depending on the symptoms.
Since this drug is administered intraarticularly, it must be performed under strict aseptic conditions.
4. Precautions for use
1. Do not administer to the following patients.
Patients with a history of hypersensitivity to the ingredients of this drug
2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to other drugs
2) Patients with hepatic impairment or a history of it (cases of AST and ALT outliers occurred in patients with a history of hepatic impairment.)
3) Patients with skin disease or infection at the injection joint (since this drug is administered within the joint)
3. Adverse reactions
1) Serious adverse reactions
Shock: Shock symptoms (frequency unknown) may occur, so observe thoroughly. If abnormalities appear, discontinue administration and take appropriate measures.
2) Other adverse reactions
① Hypersensitivity
Edema (face, eyelids, etc.), facial redness, and rarely rash, hives, and itching may occur. If such symptoms appear, stop administration and take appropriate measures.
② Administration joint
Occasionally, pain (mainly transient pain after administration), swelling, rarely dropsy, redness, heat, and severe local pressure may occur.
③ Others
Mouthfeel, vomiting, and fever may occur.
4. General precautions
1) If there is severe inflammation in the joint due to osteoarthritis of the knee, administration of this drug may cause worsening of local inflammatory symptoms, so it is advisable to administer this drug after eliminating the inflammatory symptoms.
2) Since local pain may sometimes occur due to administration of this drug, take measures such as instructing local stability after administration.
3) Since there is a risk of causing pain if it leaks outside the joint space, be sure to administer it within the joint space.
5. Application precautions
1) Precautions when injecting
① This drug is administered into the knee joint or shoulder joint, so it must be administered under strict aseptic conditions.
② If there is no improvement in symptoms, discontinue administration at the limit of 3 times.
③ When there is retention of joint fluid, the fluid is removed by paracentesis as needed.
2) Other
① Do not administer intravascularly.
② Do not use for ophthalmic purposes.
③ It is recommended to administer this drug using a needle of approximately 22-23G.
④ Be careful because this drug may cause precipitation due to quaternary ammonium salts such as benzalkonium chloride, which are disinfectants, and chlorhexidine.
6. Administration to pregnant and lactating women
1) Although the occurrence of malformations was not recognized in animal tests, its safety for pregnant women has not been established, so it should be administered cautiously to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) Avoid breast-feeding while taking this drug, as it has been confirmed in animal testing that it passes into breast milk.
7. Administration to children
Safety in children has not been established, so if administration is unavoidable, administer with caution.
8. Administration to elderly people
In general, elderly people have reduced physiological functions, so be careful.
5. How to save
Sealed container, stored at room temperature (1~30℃)
6. Packaging unit
2mL/tube × 3 tubes
7. Period of use
36 months from date of manufacture
- Active ingredient: Sodium hyaluronate (EP) ----- 10 mg
- Additives: Sodium chloride, sodium monohydrogen phosphate, sodium dihydrogen phosphate, water for injection
2. Effectiveness
Treatment of osteoarthritis of the knee joint and periarthritis of the shoulder
3. Dosage and dosage
Usually, adults administer one tube once a week into the knee joint space or shoulder joint (shoulder joint space, subacromial synovial vacuole, or biceps brachii tendon sheath) for 3 consecutive weeks. However, the number of administrations is appropriate depending on the symptoms.
Since this drug is administered intraarticularly, it must be performed under strict aseptic conditions.
4. Precautions for use
1. Do not administer to the following patients.
Patients with a history of hypersensitivity to the ingredients of this drug
2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to other drugs
2) Patients with hepatic impairment or a history of it (cases of AST and ALT outliers occurred in patients with a history of hepatic impairment.)
3) Patients with skin disease or infection at the injection joint (since this drug is administered within the joint)
3. Adverse reactions
1) Serious adverse reactions
Shock: Shock symptoms (frequency unknown) may occur, so observe thoroughly. If abnormalities appear, discontinue administration and take appropriate measures.
2) Other adverse reactions
① Hypersensitivity
Edema (face, eyelids, etc.), facial redness, and rarely rash, hives, and itching may occur. If such symptoms appear, stop administration and take appropriate measures.
② Administration joint
Occasionally, pain (mainly transient pain after administration), swelling, rarely dropsy, redness, heat, and severe local pressure may occur.
③ Others
Mouthfeel, vomiting, and fever may occur.
4. General precautions
1) If there is severe inflammation in the joint due to osteoarthritis of the knee, administration of this drug may cause worsening of local inflammatory symptoms, so it is advisable to administer this drug after eliminating the inflammatory symptoms.
2) Since local pain may sometimes occur due to administration of this drug, take measures such as instructing local stability after administration.
3) Since there is a risk of causing pain if it leaks outside the joint space, be sure to administer it within the joint space.
5. Application precautions
1) Precautions when injecting
① This drug is administered into the knee joint or shoulder joint, so it must be administered under strict aseptic conditions.
② If there is no improvement in symptoms, discontinue administration at the limit of 3 times.
③ When there is retention of joint fluid, the fluid is removed by paracentesis as needed.
2) Other
① Do not administer intravascularly.
② Do not use for ophthalmic purposes.
③ It is recommended to administer this drug using a needle of approximately 22-23G.
④ Be careful because this drug may cause precipitation due to quaternary ammonium salts such as benzalkonium chloride, which are disinfectants, and chlorhexidine.
6. Administration to pregnant and lactating women
1) Although the occurrence of malformations was not recognized in animal tests, its safety for pregnant women has not been established, so it should be administered cautiously to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) Avoid breast-feeding while taking this drug, as it has been confirmed in animal testing that it passes into breast milk.
7. Administration to children
Safety in children has not been established, so if administration is unavoidable, administer with caution.
8. Administration to elderly people
In general, elderly people have reduced physiological functions, so be careful.
5. How to save
Sealed container, stored at room temperature (1~30℃)
6. Packaging unit
2mL/tube × 3 tubes
7. Period of use
36 months from date of manufacture